Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAITHFUL Study of filgotinib add-on versus switch therapy in rheumatoid arthritis
jRCTs031230673Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of filgotinib in rheumatoid arthritis (RA) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Change in DAS28-CRP from baseline at week 24. Started May 2024; status: active, not recruiting.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs031230673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230673.